Literature DB >> 15642343

A Gly/Ala switch contributes to high affinity binding of benzoxazinone-based non-peptide oxytocin receptor antagonists.

Stuart R Hawtin1, Sookhee N Ha, Douglas J Pettibone, Mark Wheatley.   

Abstract

Non-peptide antagonists of the oxytocin receptor (OTR) have been developed to prevent pre-term labour. The benzoxazinone-based antagonists L-371,257 and L-372,662 display pronounced species-dependent pharmacology with respect to selectivity for the OTR over the V(1a) vasopressin receptor. Examination of receptor sequences from different species identified Ala(318) in helix 7 of the human OTR as a candidate discriminator required for high affinity binding. The mutant receptor [A318G]OTR was engineered and characterised using ligands representing many different chemical classes. Of all the ligands investigated, only the benzoxazinone-based antagonists had decreased affinity for [A318G]OTR. Molecular modelling revealed that Ala(318) provides a direct hydrophobic contact with a methoxy group of L-371,257 and L-372,662.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15642343     DOI: 10.1016/j.febslet.2004.10.108

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  3 in total

1.  Functional selective oxytocin-derived agonists discriminate between individual G protein family subtypes.

Authors:  Marta Busnelli; Aude Saulière; Maurice Manning; Michel Bouvier; Celine Galés; Bice Chini
Journal:  J Biol Chem       Date:  2011-11-08       Impact factor: 5.157

2.  Possible dynamic anchor points in a benzoxazinone derivative-human oxytocin receptor system--a molecular docking and dynamics calculation.

Authors:  Balázs Jójárt; Arpád Márki
Journal:  J Mol Model       Date:  2006-05-05       Impact factor: 1.810

3.  Crystal structure of the human oxytocin receptor.

Authors:  Yann Waltenspühl; Jendrik Schöppe; Janosch Ehrenmann; Lutz Kummer; Andreas Plückthun
Journal:  Sci Adv       Date:  2020-07-15       Impact factor: 14.136

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.